Skip to content


Welcome to AcuCort’s IR section

AcuCort is an innovative biotechnology company that identifies, develops and commercializes smart drugs that meet the patient’s needs for a user-friendly and effective treatment. The development candidates are based on existing and well-documented substances in indication areas where there is a great medical need and commercial interest in new and innovative products that bring benefits, such as simple administration. The approved drug is commercialized in partnership with a global network of licensees and distributors.

The company has developed and is commercializing Zeqmelit™, a fast-soluble mouth film containing the glucocorticoid dexamethasone. In the development of Zeqmelit™ ,the benefits of the well-proven and well-documented substance dexamethasone and a mouth film have been combined for quick availability and effective relief in emergency situations.

AcuCort’s ambition is to identify other existing substances that fit the company’s business model in indication areas where there are currently major medical needs. The vision is to develop and commercialize additional innovative drugs that offer both clinical relevance and patient benefits.

Contact person for IR matters is CEO Jonas Jönmark,

Financial Reports

Our financial reports are only available in Swedish.


The share


AcuCort’s share is listed on the Spotlight Stock Market since 2017 under the ticker SYMBOL ACUC and is traded through banks and fund commissioners.

AcuCort as an Investment

Four reasons to invest in AcuCort


CEO’s Christmas Letter

“AcuCort is entering a new and exciting phase, where the commercialization of our innovative and patient-friendly oral film Zeqmelit™, for the treatment of acute and severe allergic reactions, among other things, is in focus. It is gratifying that our questionnaire survey shows that an overwhelming majority, 72 percent, of the patients responding in the survey would prefer an oral film over tablets in the event of a severe allergic reaction.”

Jonas Jönmark, CEO, AcuCort AB
December 21, 2022